About Manisha Chatterjee

Since she was young, Manisha has had a strong interest in the stock market. She majored in Economics in college and has a passion for writing, which has led to her career as a research analyst. Manisha’s goal is to help individual investors succeed in the stock market. She uses her knowledge in fundamental analysis to evaluate companies and determine if they are worthwhile investments.


Recent Articles By Manisha Chatterjee

: HLIT |  News, Ratings, and Charts

4 Buy-Rated Stocks Under $10 to Add to Your Watchlist

Concerns over heightened inflation, the Fed’s tighter monetary policy, deepening supply chain constraints amid the Russia-Ukraine war, and extended lockdown measures in Chinese cities are expected to keep the stock market under pressure for an extended period. So, amid the current risk-off environment, we think it could be wise to bet on fundamentally sound low-priced stocks Harmonic (HLIT), Computer Task (CTG), Vista Energy (VIST), and The ONE Group (STKS). These stocks are rated “Buy” in our proprietary rating system. Read on.
: OI |  News, Ratings, and Charts

Is O-I Glass an Industrial Stock Worth Owning?

Glass container products manufacturer O-I Glass’ (OI) shares have soared in price over the past month, and the company was also acknowledged for its sustainability initiatives. However, is it wise to bet on the stock now despite the ongoing reorganization of its subsidiary, Paddock Enterprises? Read on to learn our view.
: COTY |  News, Ratings, and Charts

Here’s Why You Should Add Coty to Your Portfolio Now

Beauty company Coty (COTY) reported revenue growth across many of its categories in its last quarter. Also, the company expects its earnings to soar over the next few years. So, read on for details on why we think it could be wise to add the stock to one’s portfolio now.
: JNPR |  News, Ratings, and Charts

Why Juniper Networks is a Stock You Want to Own

Network product and services provider Juniper Networks (JNPR) has made consistent product and services advances and expanded its market reach over the past few months. Furthermore, it possesses sound fundamentals. So, read on for more details on why it could be wise to bet on the stock now.
: CPRX |  News, Ratings, and Charts

Catalyst Pharmaceuticals: A Biotech Stock Worth Owning

Biopharmaceutical company Catalyst Pharmaceuticals (CPRX) has been advancing with the help of its product, FIRDAPSE. Furthermore, its top and bottom line grew in its last reported quarter. So, let’s discuss in detail why it could be wise to add CPRX to one’s portfolio now. Read on.
: SENS |  News, Ratings, and Charts

Is Senseonics a Winning Diabetes Stock to Own in 2022?

Diabetes-focused medical company Senseonics (SENS) reported top- and bottom-line growth in its last reported quarter. But is it wise to bet on the stock now despite the intense competition it faces? Read on to learn our view.
: ZM |  News, Ratings, and Charts

Down Nearly 40% in the Past 3 Months, is Now a Good Time to Scoop Up Shares of Zoom Video Communications?

Despite the shares of Zoom Video Communications’ (ZM) having plunged nearly 40% in price over the past three months, the company has been making consistent product and services improvements. So, let’s evaluate if it is wise to buy the dip in the stock now.
: ADBE |  News, Ratings, and Charts

Does Adobe Stock Deserve a Place in Your Portfolio?

Even though software company Adobe (ADBE) reported average fourth-quarter results, it has made consistent product and services advancements. So, is it wise to add the stock to one’s portfolio now? Read on to learn our view.
: DCT |  News, Ratings, and Charts

Is Duck Creek Technologies a Good SaaS Stock to Own in 2022?

Software-as-a-service (SaaS) provider Duck Creek Technologies (DCT) has forged several strategic partnerships over the past few months. However, even though its top and bottom lines surged in its latest quarter, its free cash flow was negative. So, let’s evaluate if it is wise to add the stock to one’s portfolio now. Read on.
: TEVA |  News, Ratings, and Charts

Does Teva Pharmaceutical Deserve a Place in Your 2022 Portfolio?

Israel-based Teva Pharmaceutical (TEVA) is conducting trials regarding the use of opioids. But is it wise to bet on the stock now based on its sound fundamentals? Read on, let’s find out.

Page generated in 0.5866 seconds.